What is it about?
Sepragen’s single-use chromatography systems can purify biologics or gene therapy products while accommodating input from smaller bioreactors
Featured Image
Why is it important?
As productivities have improved and more niche markets and biosimilars have emerged, the age of mega-sized stainless-steel single-product plants has waned. On the rise are smaller, more targeted plants for niche markets or, increasingly, multiproduct plants.
Perspectives
Single-use chromatography systems are starting to take hold among manufacturers of biologics such as monoclonal antibodies (mAbs). As biotechnology evolves, these systems, like other single-use systems adapted for mAb production, need to be modified to help them satisfy the specific requirements of new applications.
Dr Naveen Kumar Singh
University of Notre Dame
Read the Original
This page is a summary of: Enhancing Downstream Processing of Biologics or Gene Therapies, Genetic Engineering & Biotechnology News, April 2019, Mary Ann Liebert Inc,
DOI: 10.1089/gen.39.04.17.
You can read the full text:
Contributors
The following have contributed to this page
